FDA Denies Acer’s Appeal for Edsivo, a Potential Vascular EDS Therapy
The Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has denied an appeal from Acer Therapeutics regarding Edsivo (celiprolol), an investigational therapy for vascular Ehlers-Danlos syndrome (vEDS). Further clinical studies will be needed before the investigational therapy can be resubmitted…